Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Leuk Lymphoma ; 60(13): 3188-3198, 2019 12.
Article in English | MEDLINE | ID: mdl-31190579

ABSTRACT

Multiple myeloma (MM) is a common hematological malignancy and remains incurable. MiRNA-335 is a classic tumor suppressor, yet its expression pattern and biological role in MM is unclear. The aim of the present study was to determine the expression pattern, biological role, and mechanism of miR-335 in MM. In this study, we found that miR-335 expression was decreased in MM. The promoter of miR-335 was also hypermethylated in MM. It was found that over-expression of miR-335 or 5-azacytidine treatment suppressed migration of MM cells and down-regulated the expression of IGF-1R. MiR-335 thus acts as a metastatic suppressor by targeting IGF-1R in MM. Moreover, aberrant promoter hyper-methylation is critical for miR-335 silencing in MM. We also found that miR-335 assisted in predicting both the prognosis and progression of disease in MM patients. Observations might offer a new complementary diagnostic and therapeutic target in MM.


Subject(s)
Cell Movement/genetics , MicroRNAs/metabolism , Multiple Myeloma/genetics , Receptor, IGF Type 1/genetics , Adult , Aged , Aged, 80 and over , Antimetabolites, Antineoplastic/pharmacology , Antimetabolites, Antineoplastic/therapeutic use , Azacitidine/pharmacology , Azacitidine/therapeutic use , Case-Control Studies , Cell Line, Tumor , Cell Movement/drug effects , DNA Methylation/drug effects , Down-Regulation , Epigenesis, Genetic/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Healthy Volunteers , Humans , MicroRNAs/genetics , Middle Aged , Multiple Myeloma/blood , Multiple Myeloma/drug therapy , Multiple Myeloma/pathology , Promoter Regions, Genetic/genetics
2.
Cell Death Dis ; 9(10): 993, 2018 09 24.
Article in English | MEDLINE | ID: mdl-30250169

ABSTRACT

Early evidence indicates that the long non-coding RNA CCAL plays a critical role in cancer progression and metastasis. However, the overall biological role and clinical significance of CCAL in gastric tumourigenesis and progression remain largely unknown. We observed that CCAL was upregulated in gastric cancer tissues and was associated with the tumour-node-metastasis stage. Functional experiments showed that CCAL promoted gastric cancer cell proliferation and metastasis in vitro and in vivo. Luciferase reporter assay indicated that CCAL directly bind to miR-149. Moreover, knockdown of CCAL significantly reduced the expression of FOXM1, a direct target of miR-149. We also showed that FOXM1 suppression by miR-149 could be partially rescued by CCAL overexpression. In addition, we identified a negative correlation between the mRNA expression of CCAL and miR-149 in gastric cancer tissues. Furthermore, we observed a negative correlation between the expression of miR-149 and FOXM1 and a positive correlation between CCAL and FOXM1 levels. These results demonstrated that the CCAL/miR-149/FOXM1 axis functions as a key regulator in gastric cancer metastasis and CCAL potentially represents a biomarker for diagnosis and potential target for therapy in the future.


Subject(s)
Forkhead Box Protein M1/metabolism , MicroRNAs/metabolism , RNA, Long Noncoding/metabolism , Stomach Neoplasms/pathology , Apoptosis , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Cell Cycle , Cell Line, Tumor , Cell Movement , Cell Proliferation , Disease Progression , Female , Gene Knockdown Techniques , Humans , Male , Middle Aged , Neoplasm Metastasis , RNA, Long Noncoding/genetics , Stomach Neoplasms/metabolism , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...